A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice

Gene Therapy

Volumn 10, Issue 6, 2003, Pages 478-489

  Eliopoulos, N ^a   Al Khaldi, A ^b   Crosato, M ^a   Lachapelle, K ^b   Galipeau, J ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cell therapy; Erythropoietin; Gene transfer; Marrow stroma; Retroviral vector

Indexed keywords

COLLAGEN; ERYTHROPOIETIN; MATRIGEL;

ANGIOGENESIS; ANIMAL CELL; BONE MARROW; CONTROLLED STUDY; GENETIC ENGINEERING; HEMATOCRIT; IMPLANT; MESENCHYME; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASTICITY; PRIORITY JOURNAL; PROTEIN SECRETION; RETROVIRUS; REVIEW; STROMA CELL; TRANSGENE;

ANIMALS; BONE MARROW CELLS; CELL TRANSPLANTATION; COLLAGEN; DRUG COMBINATIONS; ERYTHROPOIETIN; FEMALE; GENE THERAPY; GENETIC VECTORS; HEMATOCRIT; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; LAMININ; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANOIDS; PROTEOGLYCANS; RETROVIRIDAE;

ANIMALIA; BOVINAE; UNIDENTIFIED RETROVIRUS;

EID: 0344642954     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301919     Document Type: Review

References (80)

1. Maione D et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000; 11: 859-868.
2. Descamps V et al. Erythropoietin gene transfer and expression in adult normal mice: use of an adenovirus vector. Hum Gene Ther 1994; 5: 979-985.
3. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
4. Tripathy SK et al. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91: 11557-11561.
5. Svensson EC et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 1997; 8: 1797-1806.
6. Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082-14087.
7. Snyder RO et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
8. Zhou S, Murphy JE, Escobedo JA, Dwarki VJ. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther 1998; 5: 665-670.
9. Bohl D et al. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 2000; 95: 2793-2798.
10. Beall CJ et al. Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector. Gene Ther 2000; 7: 534-539.
11. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery [review] [63 refs]. Curr Opin Biotechnol 1999; 10: 440-447.
12. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? [review] [48 refs]. Gene Ther 2000; 7: 24-30.
13. Moskalenko M et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
14. Lochmuller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. Biochem Biophys Res Commun 1995; 213: 569-574.
15. Miller HI. Gene therapy on trial. Science 2000; 287: 591-592.
16. Wadman M. NIH under fire over gene-therapy trials. Nature 2000; 403: 237.
17. Jenks S. Gene therapy death - 'Everyone has to share in the guilt'. J Nat Cancer Inst 2000; 92: 98-100.
18. Donsante A et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors [letter; comment]. Gene Ther 2001; 8: 1343-1346.
19. Rizzuto G et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999; 96: 6417-6422.
20. Payen E et al. Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. Exp Hematol 2001; 29: 295-300.
21. Rizzuto G et al. Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000; 11: 1891-1900.
22. Maruyama H et al. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 2000; 11: 429-437.
23. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250.
24. Jiao S et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992; 3: 21-33.
25. Tripathy SK et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93: 10876-10880.
26. Roth DA et al. Non-viral gene transfer of blood coagulation factor VIII in patients with severe hemophilia A. Blood 2000; 96: 590 (abstract).
27. Ding L et al. Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther 1999; 6: 1611-1616.
28. Clark BR, Keating A. Biology of bone marrow stroma [review] [57 refs]. Ann NY Acad Sci 1995; 770: 70-78.
29. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses [review] [92 refs]. Exp Hematol 2000; 28: 875-884.
30. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues [review] [32 refs]. Science 1997; 276: 71-74.
31. Gerson SL. Mesenchymal stem cells: no longer second class marrow citizens [news; comment]. Nat Med 1999; 5: 262-264.
32. Makino S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705.
33. Reyes M et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615-2625.
34. Horwitz EM et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313.
35. Horwitz EM et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-1231.
36. Keating A et al. Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man. Nature 1982; 298: 280-283.
37. Jaalouk DE et al. Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Hum Gene Ther 2000; 11: 1837-1849.
38. Chiang GG et al. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648. Hum Gene Ther 1999; 10: 61-76.
39. Hurwitz DR et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997; 8: 137-156.
40. Keating A, Guinn BA, Laraya P, Wang XH. Human marrow stromal cells electrotransfected with human FIX cDNA engraft in SCID mice and transcribe human Factor IX. Exp Hematol 1996; 24: 1056 (abstract).
41. Eliopoulos N, Crosato M, and Galipeau J. High-level erythropoietin production from genetically engineered bone marrow stroma implanted in non-myeloablated, immunocompetent mice. Blood 2000; 96: 802 (absract).
42. Nolta JA, Hanley MB, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood 1994; 83: 3041-3051.
43. Brouard N et al. Transplantation of stromal cells transduced with the human IL3 gene to stimulate hematopoiesis in human fetal bone grafts in non-obese, diabetic-severe combined immunodeficiency mice. Leukemia 1998; 12: 1128-1135.
44. Cherington V et al. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Hum Gene Ther 1998; 9: 1397-1407.
45. Bartholomew A et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12: 1527-1541.
46. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
47. Galipeau J et al. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res 1999; 59: 2384-2394.
48. Morgenstern JP, Land H. A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990; 18: 1068.
49. Regulier E et al. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 1998; 5: 1014-1022.
50. Rinaudo D, Toniatti C. Sensitive ELISA for mouse erythropoietin. Biotechniques 2000; 29: 218-220.
51. Naffakh N et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 1996; 7: 11-21.
52. Lejnieks DV, Ramesh N, Lau S, Osborne WR. Stomach implant for long-term erythropoietin expression in rats. Blood 1998; 92: 888-893.
53. Lin Y et al. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002; 99: 457-462.
54. Ramesh N et al. High-level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum Gene Ther 1993; 4: 3-7.
55. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991; 88: 1330-1334.
56. Cristofalo VJ, Volker C, Francis MK, Tresini M. Age-dependent modifications of gene expression in human fibroblasts [review] [261 refs]. Crit Rev Eukaryotic Gene Expression 1998; 8: 43-80.
57. Gussoni E et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 1992; 356: 435-438.
58. Mendell JR et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy [see comments]. New Engl J Med 1995; 333: 832-838.
59. Morgan JE. Cell and gene therapy in Duchenne muscular dystrophy [review]. [104 refs]. Hum Gene Ther 1994; 5: 165-173.
60. Osborne WR et al. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8058.
61. Clowes MM et al. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644-651.
62. Lejnieks DV et al. Granulocyte colony-stimulating factor expression from transduced vascular smooth muscle cells provides sustained neutrophil increases in rats. Hum Gene Ther 1996; 7: 1431-1436.
63. Mitani K, Wakamiya M, Caskey CT. Long-term expression of retroviral-transduced adenosine deaminase in human primitive hematopoietic progenitors. Hum Gene Ther 1993; 4: 9-16.
64. Chertkov JL et al. The hematopoietic stromal microenvironment promotes retrovirus-mediated gene transfer into hematopoietic stem cells. Stem Cells 1993; 11: 218-227.
65. Quesenberry PJ et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells 1994; 20: 348-350.
66. Culver K et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA 1991; 88: 3155-3159.
67. Koc ON et al. Culture-expanded autologous human mesenchymal stem cells (MSCs) circulate in blood and retain proliferative capacity following iv infusion into breast cancer patients. Blood 1998; 92: 274 (abstract).
68. Lazarus HM et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
69. Keating A, Berkahn L, Filshie R. A phase I study of the transplantation of genetically marked autologous bone marrow stromal cells. Hum Gene Ther 1998; 9: 591-600.
70. Chuah MK et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000; 11: 729-738.
71. Allay JA et al. LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. Hum Gene Ther 1997; 8: 1417-1427.
72. Pereira RF et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998; 95: 1142-1147.
73. Koc ON, Lazarus HM. Mesenchymal stem cells: heading into the clinic [review]. Bone Marrow Transplant 2001; 27: 235-239.
74. Naffakh N et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 1995; 92: 3194-3198.
75. Rosenzweig M et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood 2001; 97: 1951-1959.
76. Stripecke R et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305-1312.
77. Stupack DG et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001; 155: 459-470.
78. Jiang Y et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49.
79. Ruschitzka FT et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000; 97: 11609-11613.
80. Eliopoulos N et al. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther 2002; 9: 452-462.